Jonathan E Dowell

Summary

Affiliation: University of Texas Southwestern Medical Center
Country: USA

Publications

  1. doi request reprint A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
    Jonathan E Dowell
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Lung Cancer 77:567-71. 2012
  2. ncbi request reprint Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2
    Jonathan E Dowell
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Anticancer Res 24:2367-73. 2004
  3. doi request reprint Small cell lung cancer: are we making progress?
    Jonathan E Dowell
    Hematology Oncology, Veterans Affairs North Texas Healthcare System, Dallas, Texas, USA
    Am J Med Sci 339:68-76. 2010
  4. ncbi request reprint Antiangiogenic therapies for mesothelioma
    Jonathan E Dowell
    University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Hematol Oncol Clin North Am 19:1137-45, viii. 2005
  5. ncbi request reprint ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation
    Mose Hayes
    Sacred Heart Medical Oncology, Miramar Beach, FL, USA
    Anticancer Res 31:4135-9. 2011
  6. pmc Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy
    David E Gerber
    Department of Internal Medicine, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Thorac Oncol 6:365-71. 2011
  7. pmc Consent timing and experience: modifiable factors that may influence interest in clinical research
    David E Gerber
    University of Texas Southwestern Medical Center, Dallas, TX
    J Oncol Pract 8:91-6. 2012
  8. pmc Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population
    Drew W Rasco
    Department of Internal Medicine Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    J Thorac Oncol 5:1529-35. 2010
  9. ncbi request reprint Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer
    L Chinsoo Cho
    Department of Radiation Oncology, UT Southwestern Medical Center at Dallas, Moncrief Radiation Oncology Center, Harold C Simmons Comprehensive Cancer Center, Dallas, TX 75390, USA
    Semin Oncol 32:293-8. 2005
  10. doi request reprint The impact of consenter characteristics and experience on patient interest in clinical research
    Drew W Rasco
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Oncologist 14:468-75. 2009

Detail Information

Publications20

  1. doi request reprint A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma
    Jonathan E Dowell
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Lung Cancer 77:567-71. 2012
    ..We evaluated the addition of bevacizumab to cisplatin and pemetrexed as first-line treatment in patients with advanced, unresectable MM...
  2. ncbi request reprint Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2
    Jonathan E Dowell
    Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8852, USA
    Anticancer Res 24:2367-73. 2004
    ..Little is known about the frequency of tumor expression of VEGF and COX-2 in SCLC or the prognostic significance of this expression...
  3. doi request reprint Small cell lung cancer: are we making progress?
    Jonathan E Dowell
    Hematology Oncology, Veterans Affairs North Texas Healthcare System, Dallas, Texas, USA
    Am J Med Sci 339:68-76. 2010
    ..Although initial attempts at "targeted therapy" in SCLC have been unsuccessful, several newly identified targets hold promise and give hope that significant improvements in therapy for this challenging disease are not far away...
  4. ncbi request reprint Antiangiogenic therapies for mesothelioma
    Jonathan E Dowell
    University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Hematol Oncol Clin North Am 19:1137-45, viii. 2005
    ..Several clinical trials are currently evaluating the efficacy of inhibitors of angiogenesis in mesothelioma. This article details the preliminary results of these trials and future directions...
  5. ncbi request reprint ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation
    Mose Hayes
    Sacred Heart Medical Oncology, Miramar Beach, FL, USA
    Anticancer Res 31:4135-9. 2011
    ..Overexpression of excision repair cross complementing group 1 (ERCC1), a DNA repair enzyme, is associated with resistance to cisplatin...
  6. pmc Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy
    David E Gerber
    Department of Internal Medicine, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    J Thorac Oncol 6:365-71. 2011
    ..We, therefore, determined the predictors and impact of second-line chemotherapy administration in a contemporary, diverse NSCLC population...
  7. pmc Consent timing and experience: modifiable factors that may influence interest in clinical research
    David E Gerber
    University of Texas Southwestern Medical Center, Dallas, TX
    J Oncol Pract 8:91-6. 2012
    ..However, few studies have examined factors related to the consent process. We therefore evaluated the impact of consent timing and experience on markers of patient interest in research...
  8. pmc Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population
    Drew W Rasco
    Department of Internal Medicine Hematology Oncology, Harold C Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390 8852, USA
    J Thorac Oncol 5:1529-35. 2010
    ..Therefore, we determined the use of chemotherapy in a contemporary, diverse NSCLC population encompassing all patient ages...
  9. ncbi request reprint Prophylactic cranial irradiation with combined modality therapy for patients with locally advanced non-small cell lung cancer
    L Chinsoo Cho
    Department of Radiation Oncology, UT Southwestern Medical Center at Dallas, Moncrief Radiation Oncology Center, Harold C Simmons Comprehensive Cancer Center, Dallas, TX 75390, USA
    Semin Oncol 32:293-8. 2005
    ..The results from the Radiation Therapy Oncology Group (RTOG) trial of PCI to prevent CNS relapse in patients with locally advanced NSCLC are anticipated...
  10. doi request reprint The impact of consenter characteristics and experience on patient interest in clinical research
    Drew W Rasco
    Division of Hematology Oncology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390 8852, USA
    Oncologist 14:468-75. 2009
    ..However, the impact of nonphysician research personnel, who often consent patients for studies, is unclear. We therefore evaluated the association between consenter characteristics and subject interest in clinical research...
  11. pmc Upper extremity venous thrombosis in patients with cancer with peripherally inserted central venous catheters: a retrospective analysis of risk factors
    Daniel H Ahn
    University of Texas Southwestern Medical Center, Department of Palliative Care, Dallas, TX 75390 8889, USA
    J Oncol Pract 9:e8-12. 2013
    ..One common complication associated with their use is upper extremity venous thrombosis (UEVT). The purpose of this study was to ascertain risk factors associated with an increased risk of PICC-associated UEVT in patients with cancer...
  12. doi request reprint Incidence of isolated heparin-induced thrombocytopenia and risk of thrombosis by IgG-specific anti-PF4/heparin ELISA
    Sofyan M Radaideh
    Division of Hematology Oncology, Department of Medicine, UT Southwestern Medical Center at Dallas, TX, USA
    Clin Appl Thromb Hemost 18:215-7. 2012
    ..However, the impact of using the IgG-ELISA on the incidence of isolated HIT (thrombocytopenia alone without clinically evident thrombosis) and the risk of developing subsequent thrombosis are still unknown...
  13. doi request reprint Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid
    Sachin R Shah
    Texas Tech University Health Sciences Center TTUHSC School of Pharmacy, 4500 S Lancaster Rd, Dallas, TX 75216, USA
    Support Care Cancer 20:87-93. 2012
    ....
  14. ncbi request reprint EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer
    Jonathan E Dowell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Nat Clin Pract Oncol 3:170-1. 2006
  15. ncbi request reprint Epidermal growth factor receptor mutations in non-small cell lung cancer: a basic science discovery with immediate clinical impact
    Jonathan E Dowell
    Departments of Internal Medicine, University of Texas Southwestern Medical Center, and the Dallas Veterans Affairs Medical Center, Dallas, Texas 75390 8852, USA
    Am J Med Sci 331:139-49. 2006
    ..This discovery has far-reaching implications, not only for lung cancer patients treated with an EGFR TKI but also for future drug development in all malignancies...
  16. doi request reprint Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer
    Arkadiusz Z Dudek
    University of Minnesota Comprehensive Cancer Center, Minneapolis, Minnesota 55455, USA
    J Thorac Oncol 3:394-9. 2008
    ..Pemetrexed is synergistic with gemcitabine in preclinical models of non-small cell lung cancer (NSCLC). The optimal dose and utility of gemcitabine and pemetrexed was evaluated in a dose-escalating study...
  17. ncbi request reprint A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871
    Lionel D Lewis
    Sections of Clinical Pharmacology and Hematology Oncology, Department of Medicine, Dartmouth Medical School, The Norris Cotton Cancer Center, Lebanon, New Hampshire 03756, USA
    Clin Cancer Res 13:3302-11. 2007
    ..We hypothesized that the pharmacokinetics and pharmacodynamics of docetaxel, an i.v. administered cytotoxic and substrate for CYP3A4, CYP3A5, and ABCB1, would differ between African-American and Caucasian patients...
  18. ncbi request reprint The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy
    Jonathan E Dowell
    Dallas Veterans Affairs Medical Center, TX, USA
    Nat Clin Pract Oncol 1:2-3. 2004
  19. ncbi request reprint Case 1. Melanoma in African Americans
    Jonathan E Dowell
    Dallas Veterans Affairs Medical Center, TX, USA
    J Clin Oncol 23:3622-4. 2005
  20. ncbi request reprint Chasing mutations in the epidermal growth factor in lung cancer
    Jonathan E Dowell
    N Engl J Med 352:830-2. 2005